After the benchmark S&P/ASX 200 surged 7.5 per cent in 2024, investors are looking to see where the growth will come from in ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

The advent of a Trump presidency is accelerating a divergence on digital currencies between the world’s two largest economies ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip cashed in on major ...

Aubiotech hopes to score some quick runs with a pre-budget submission on ways to fix the sector's "stubborn issues" ...